Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials - Concepedia

Concepedia

Publication | Open Access

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

DOI Full Paper Access

33

Citations

64

References

2013

Year

George Fountzilas, Urania Dafni, Mattheos Bobos, Vassiliki Kotoula, Anna Batistatou, Ioannis Xanthakis, Christos Papadimitriou, Ioannis Kostopoulos, Triantafyllia Κoletsa, Eleftheria Tsolaki,

Abstract

Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12611000506998 and ACTRN12609001036202.

References

	Year	Citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Cancer Statistics, 2009 Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward, CA A Cancer Journal for Clinicians Epidemiology Of CancerPathologyCancer RegistrationMortality RatesUnited States	2009	9.7K
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Journal of Clinical Oncology	2006	4.5K
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett, Journal of Clinical Oncology	2010	4.2K
Tissue microarrays for high-throughput molecular profiling of tumor specimens Juha Kononen, Lukas Bubendorf, Anne Kallionimeni, Nature Medicine EngineeringTumor HeterogeneityComputational BiologyBiostatisticsGene Expression Profiling	1998	4.1K
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer Maggie C.U. Cheang, Stephen Chia, David Voduc, JNCI Journal of the National Cancer Institute	2009	2.2K
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei, JNCI Journal of the National Cancer Institute Prognostic EvaluationPrognostic BiomarkersCancer DiagnosticsRelated MarkersCancer Detection	2005	2.1K
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers Richard Simon, Seungmok Paik, Daniel F. Hayes JNCI Journal of the National Cancer Institute	2009	1K
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System Clifford A. Hudis, William E. Barlow, Joseph P. Costantino, Journal of Clinical Oncology	2007	860
A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription Bong‐Gun Ju, Victoria V. Lunyak, Valentina Perissi, Science Histone ModificationsMolecular BiologyMultiple Enzymatic ActivitiesEpigeneticsRegulated Transcription	2006	833

Page 1